NCT06151847 2024-02-28
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
University of Kansas Medical Center
Phase 2 Unknown
Clinical Trials
21 trialsNCT05590221 2024-01-08
Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT04989335 2023-11-28
Bisantrene Combination for Resistant AML
Sheba Medical Center
Phase 2 Unknown
NCT05322330 2023-02-09
Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05322733 2022-04-19
Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05287984 2022-03-31
ZFCR/ZBR
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Unknown
NCT05084027 2021-10-27
Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT03648697 2020-08-11
EBV-TCR-T（YT-E001）for Patients With EBV-positive Recurrent or Metastatic NPC
Fujian Cancer Hospital
Phase 2 Unknown
NCT02638428 2020-03-19
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
Phase 2 Unknown
NCT03412526 2019-04-04
Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian
Sheba Medical Center
Phase 2 Unknown
NCT02333838 2018-08-13
TBF-Cord
Assistance Publique - Hôpitaux de Paris
Phase 2 Unknown
NCT03335241 2017-11-13
Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT03016988 2017-01-11
The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma
Fujian Medical University
Phase 2 Unknown
NCT02275663 2015-01-06
Azacytidine Plus FLAG for Relapsed or Refractory AML
King Fahad Medical City
Phase 2 Unknown
NCT02049580 2014-01-30
Reduced Intensity Conditioning (RIC) Regimen and Post-transplant Cyclophosphamide in Haploidentical Bone Marrow Transplantation in in Patients With Poor Prognosis Lymphomas
Istituto Clinico Humanitas
Phase 2 Unknown
NCT01810926 2013-03-14
T&B Depletion Non Malignant
Bambino Gesù Hospital and Research Institute
Phase 2 Unknown
NCT00737685 2012-03-26
Flu+CPM+rATG Conditioning Regimes for Unrelated Bone Marrow Transplantation (UBMT)(or Mobilized Peripheral Blood)in Severe Aplastic Anemia (SAA)
The Korean Society of Pediatric Hematology Oncology
Phase 2 Unknown
NCT00840385 2010-09-15
FAD
Fudan University
Phase 2 Unknown
NCT00815568 2008-12-30
Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI)
Samsung Medical Center
Phase 2 Unknown
NCT00529880 2007-09-27
Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML
Cooperative Study Group A for Hematology
Phase 2 Unknown
NCT00382694 2006-09-29
Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients
Nordic Myeloma Study Group
Phase 2 Unknown